Search

Your search keyword '"Deutschmann, Daniela"' showing total 6 results
Start Over Author "Deutschmann, Daniela"
6 results on '"Deutschmann, Daniela"'

2. Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus–Specific CD8 T-Cell Responses and High Anti–Hepatitis B Surface Antigen Titers.

Author

Schmidt, Sarah, Mengistu, Meron, Daffis, Stephane, Ahmadi-Erber, Sarah, Deutschmann, Daniela, Grigoriev, Tetiana, Chu, Ruth, Leung, Cleo, Tomkinson, Adrian, Uddin, Mohammad Nizam, Moshkani, Safiehkhatoon, Robek, Michael D, Perry, Jason, Lauterbach, Henning, Orlinger, Klaus, Fletcher, Simon P, and Balsitis, Scott

Subjects
CELL surface antigens, HEPATITIS B, CD8 antigen, LYMPHOCYTIC choriomeningitis virus, TITERS
Abstract

Hepatitis B Virus (HBV) is a major driver of infectious disease mortality. Curative therapies are needed and ideally should induce CD8 T cell-mediated clearance of infected hepatocytes plus anti-hepatitis B surface antigen (HBsAg) antibodies (anti-HBs) to neutralize residual virus. We developed a novel therapeutic vaccine using non-replicating arenavirus vectors. Antigens were screened for genotype conservation and magnitude and genotype reactivity of T cell response, then cloned into Pichinde virus (PICV) vectors (recombinant PICV, GS-2829) and lymphocytic choriomeningitis virus (LCMV) vectors (replication-incompetent, GS-6779). Alternating immunizations with GS-2829 and GS-6779 induced high-magnitude HBV T cell responses, and high anti-HBs titers. Dose schedule optimization in macaques achieved strong polyfunctional CD8 T cell responses against core, HBsAg, and polymerase and high titer anti-HBs. In AAV-HBV mice, GS-2829 and GS-6779 were efficacious in animals with low pre-treatment serum HBsAg. Based on these results, GS-2829 and GS-6779 could become a central component of cure regimens. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive HBV-specific CD8 T cell responses and high anti-HBs titers

Author

Schmidt, Sarah, primary, Mengistu, Meron, additional, Daffis, Stephane, additional, Ahmadi-Erber, Sarah, additional, Deutschmann, Daniela, additional, Grigoriev, Tetiana, additional, Chu, Ruth, additional, Leung, Cleo, additional, Tomkinson, Adrian, additional, Uddin, Mohammad Nizam, additional, Moshkani, Safiehkhatoon, additional, Robek, Michael D, additional, Perry, Jason, additional, Lauterbach, Henning, additional, Orlinger, Klaus, additional, Fletcher, Simon P, additional, and Balsitis, Scott, additional

Published
2023
Full Text
View/download PDF

4. Abstract 4198: Evaluation of a cancer immunotherapy with engineered arenavirus vectors and 4-1BB agonists in a preclinical tumor model

Author

Strauss, Judith, primary, Scheinost, Marilies, additional, Kleissner, Theresa, additional, Reckendorfer, Diana, additional, Pojar, Kimberly, additional, Habbeddine, Mohamed, additional, Ahmadi-Erber, Sarah, additional, Deutschmann, Daniela, additional, Schmidt, Sarah, additional, Raguz, Josipa, additional, Matushansky, Igor, additional, Lampert, Christoph, additional, Orlinger, Klaus K., additional, and Lauterbach, Henning, additional

Published
2022
Full Text
View/download PDF

5. Active Human Complement Reduces the Zika Virus Load via Formation of the Membrane-Attack Complex

Author

Schiela, Britta, Bernklau, Sarah, Malekshahi, Zahra, Deutschmann, Daniela, Koske, Iris, Banki, Zoltan, Thielens, Nicole, Würzner, Reinhard, Speth, Cornelia, Weiss, Guenter, Stiasny, Karin, Steinmann, Eike, Stoiber, Heribert, Innsbruck Medical University [Austria] (IMU), Institut de biologie structurale (IBS - UMR 5075 ), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Medizinische Universität Wien = Medical University of Vienna, Department of Molecular and Medical Virology, Ruhr University Bochum (RUB), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)

Subjects
lcsh:Immunologic diseases. Allergy, IgM, MAC, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], Complement C1q, viruses, Immunology, Complement Membrane Attack Complex, Viral Load, Viral Nonstructural Proteins, Antibodies, Viral, Cell Line, Zika virus, Immunoglobulin M, Aedes, Animals, Humans, complement, lcsh:RC581-607, C1q, Original Research, lysis
Abstract

International audience; Although neglected in the past, the interest on Zika virus (ZIKV) raised dramatically in the last several years. The rapid spread of the virus in Latin America and the association of the infection with microcephaly in newborns or Guillain-Barré Syndrome in adults prompted the WHO to declare the ZIKV epidemic to be an international public health emergency in 2016. As the virus gained only limited attention in the past, investigations on interactions of ZIKV with human complement are limited. This prompted us to investigate the stability of the virus to human complement. At low serum concentrations (10%) which refers to complement concentrations found on mucosal surfaces, the virus was relatively stable at 37°C, while at high complement levels (50% serum concentration) ZIKV titers were dramatically reduced, although the virus remained infectious for about 4–5 min under these conditions. The classical pathway was identified as the main actor of complement activation driven by IgM antibodies. In addition, direct binding of C1q to both envelope and NS1 proteins was observed. Formation of the MAC on the viral surface and thus complement-mediated lysis and not opsonization seems to be essential for the reduction of viral titers.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results